CoreCap Advisors’s LENZ Therapeutics LENZ Stock Holding History

CoreCap Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$932	Buy	+164	New	+$1.32K	﹤0.01%	2713
2025 Q4	–	Sell	-3,000	Closed	-$140K	–	3072
2025 Q3	$140K	Buy	+3,000	New	+$110K	0.01%	916
2025 Q2	–	Sell	-38	Closed	-$977	–	3297
2025 Q1	$977	Sell	38 -63	-62%	-$1.55K	﹤0.01%	2530
2024 Q4	$2.92K	Buy	+101	New	+$3.08K	﹤0.01%	2124

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

CoreCap Advisors's LENZ Position: Q2 2026 in Review

CoreCap Advisors opened a new position in LENZ Therapeutics (LENZ) in Q2 2026: 164 shares worth $932. The stake represents ﹤0.01% of the portfolio and ranks #2713 among its holdings. This is a return to the name: CoreCap Advisors previously reported a position in LENZ as recently as Q3 2025.

CoreCap Advisors first reported a position in LENZ in Q4 2024 and has held it in 4 quarters since. The position peaked at $140K in Q3 2025. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

CoreCap Advisors held 164 shares of LENZ Therapeutics worth $932 as of Q2 2026.
LENZ Therapeutics was a new CoreCap Advisors position in Q2 2026.
LENZ Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2713 holding.
CoreCap Advisors first reported a position in LENZ Therapeutics in Q4 2024 and has held it in 4 quarters since.
CoreCap Advisors's LENZ Therapeutics position peaked at $140K in Q3 2025.
144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.